Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Partnering to build biosynthesis processes and a pharmaceutical production platform
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Flattish volume growth and subdued new launches were key factors for last month
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
Subscribe To Our Newsletter & Stay Updated
